Avicanna Latam launches re+PLAY CBD wellness brand

Ms. Ivana Maric reports AVICANNA LATAM SAS TEAMS UP WITH HARRINGTON WELLNESS TO LAUNCH RE+PLAY CBD WELLNESS BRAND TOPICALS IN THE UNITED STATES Avicanna Inc. subsidiary Avicanna Latam SAS is an international biopharmaceutical company based in Colombia and focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products. Avicanna Latam, a wholly owned subsidiary of Avicanna, is pleased to announce the launch of the re+PLAY CBD wellness brand with Harrington Wellness nationwide across the United States. re+PLAY is a cannabidiol wellness brand built with collaborative effort from scientists, athletes, doctors and certified athletic trainers. Avicanna Latam and Harrington Wellness have collaborated over several years on the research and development of these cannabidiol-based topicals inspired by the athletic and sports community. These cannabidiol-based topicals utilize Avicanna's proprietary and drug delivery systems, organic hemp-derived cannabinoids and international manufacturing with the support of Harrington Wellness's deep understanding of professional athletes and their needs. "As a business executive and former professional athlete, I'm proud to expand our collaboration with Avicanna to introduce this unique and scientifically backed line of CBD wellness products to the United States," stated Al Harrington, chief executive officer of Harrington Wellness. Initial product offerings include a 3-per-cent CBD localized cream and 2-per-cent CBD and 1-per-cent cannabigerol transdermal gel utilizing Avicanna's patented deep tissue technology. The CBD and CBG used in the formulations were derived from USDA organic certified hemp cultivated in Avicanna's subsidiary Santa Marta Golden Hemp and manufactured by Avicanna Latam's team in Colombia. About Avicanna Inc. Avicanna Latam, a wholly owned subsidiary of Avicanna, is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna Latam and Avicanna have an established scientific platform including research and development and clinical development leading to the commercialization around the world of more than 30 proprietary, evidence-based finished products and supporting four commercial-stage business pillars: Medical cannabis formulary (RHO Phyto): The formulary offers a diverse range of proprietary products, including oral, sublingual, topical and transdermal deliveries with varying ratios of cannabinoids, supported by continuing patient and medical community education. RHO Phyto products are not available in the United States. Medical cannabis care platform (MyMedi): In Canada, Avicanna owns MyMedi, which is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. MyMedi is operated by Northern Green Canada Inc., and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi is not intended for U.S. audiences, and products are not available to those who reside in the United States. Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration and real-world evidence, Avicanna Latam has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development in Latin America and elsewhere around the world. Active pharmaceutical ingredients (Aureus Santa Marta): Active pharmaceutical ingredients supplied by Avicanna Latam's subsidiary Santa Marta Golden Hemp is a commercial-stage business dedicated to providing various forms of high-quality CBD, tetrahydrocannabinol and CBG to Avicanna Latam's international partners for use in the development and production of food, cosmetics, medical and pharmaceutical products. SMGH also forms part of the Avicanna's global supply chain, and is a source of reliable input products for its consumer retail, medical cannabis and pharmaceutical products globally. We seek Safe Harbor.